PD-1/PD-L1抑制剂治疗晚期非小细胞肺癌的研究进展

Research progress of PD-1/PD-L1 inhibitors in the treatment of advanced non-small cell lung cancer

肺癌是目前世界上最常见的恶性肿瘤之一,病死率居于所有恶性肿瘤的首位,其中非小细胞肺癌所占比例最高。非小细胞肺癌的传统治疗效果不近人意,迫切需要探索新疗法来打破这一瓶颈。近年来,以程序性死亡分子-1(PD-1)及其配体(PD-L1)抑制剂为代表的免疫治疗在晚期非小细胞肺癌中取得了突破性进展,但仍存在诸多问题亟待解决。本文对PD-1/PD-L1抑制剂在晚期非小细胞肺癌(NSCLC)中的临床疗效、药物不良反应、单药或联合用药及寻找预测疗效的理想标志物的研究进展做一综述。

Lung cancer is one of the most common malignant tumors in the world,and the mortality rate ranks first among all malignant tumors,of which non-small cell lung cancer (NSCLC)accounts for the highest proportion.The traditional treatment of NSCLC is not satisfactory,so it is urgent to explore new therapy to break the bottleneck.In re- cent years,immunotherapy represented by programmed death 1 (PD-1)and programmed death ligand 1 (PD-L1)inhibitots has made breakthroughs in the treatment of advanced NSCLC,but there are still many problems to be solved.This article reviews the progress of PD-1/PD-L1 inhibitors in the treatment of advanced NSCLC,including clinical efficacy, adverse drug reactions,monotherapy or combined treatment,and the search for ideal biomarkers for predictive efficacy.